Named CTA families and studied targets
This explicit panel contains 113 protein records from the named MAGE-A/B/C, SSX, GAGE, PAGE, XAGE, BAGE, CT45/47, SPANX, TSPY and CSAG families, plus individually listed targets. SSX2IP is not an SSX antigen-family member and is excluded from this panel. BAGE has no resolved record in the current reference identity catalog; no category is inferred for that missing identity. Family membership and historical nomination do not override a normal-expression exclusion. The table uses current protein records, so identical-reference loci can share a row. The CSV retains every member gene, transcript and paper link.
Current means the corrected fivefold-rule draft; proposed means the tenfold single-tumor alternative. The two-patient route is unchanged. Unsafe records retain the existing normal/clinical screen. Gate names identify the recorded cause; they do not assert that clinical injury has been proved for every protein. The current full inventory includes proteins outside this named panel.
| Protein | Current classification | Proposed classification | Recorded reason | Exact-locus published nominations |
|---|---|---|---|---|
| ACRBP · HPA | Unsafe | Unsafe | Normal bulk ; HPA tissue clusters ; HPA immune ; Monaco immune ; DICE immune | Chang et al. (2019); Wang et al. (2016) |
| AKAP4 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Wang et al. (2016); da Silva et al. (2017) |
| CAGE1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Wang et al. (2016); da Silva et al. (2017) |
| CEP55 · HPA | Unsafe | Unsafe | HPA normal protein ; Normal bulk ; HPA tissue clusters ; DICE immune ; Adult cornea ; Rare vital-tissue cell expression | — |
| CSAG1 · HPA | Unsafe | Unsafe | Rare vital-tissue cell expression | Wang et al. (2016) |
| CSAG2 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Jamin et al. (2021) |
| CSAG3 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Jamin et al. (2021) |
| CT45A1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Jamin et al. (2021); Loriot et al. (2025); da Silva et al. (2017) |
| CT45A10 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Loriot et al. (2025) |
| CT45A2/8/9 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Jamin et al. (2021); Loriot et al. (2025); da Silva et al. (2017) |
| CT45A3 · HPA | Other:Sequence | Other:Sequence | Nested or Unsafe-contained sequence | Jamin et al. (2021); Loriot et al. (2025); da Silva et al. (2017) |
| CT45A5/6/7 · HPA | Unsafe | Unsafe | Normal bulk | Jamin et al. (2021); Loriot et al. (2025); da Silva et al. (2017) |
| CT47A1/10/11/12/2/3/4/5/6/7/8/9 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Loriot et al. (2025); Wang et al. (2016) |
| CT83 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| CTAG2 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Loriot et al. (2025); Seager et al. (2024); da Silva et al. (2017) |
| CTAGE1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | da Silva et al. (2017) |
| CTCFL · HPA | Unsafe | Unsafe | Normal bulk | Bruggeman et al. (2018); Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| DDX43 · HPA | Unsafe | Unsafe | HPA normal protein ; HPA tissue clusters ; Monaco immune ; DICE immune ; Rare vital-tissue cell expression | Bruggeman et al. (2018); Chang et al. (2019); Wang et al. (2016) |
| DPEP3 · HPA | Unsafe | Unsafe | Normal bulk ; Monaco immune | Bruggeman et al. (2018); Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| FATE1 · HPA | Unsafe | Unsafe | HPA tissue clusters ; Rare vital-tissue cell expression | Bruggeman et al. (2018); Chang et al. (2019); Wang et al. (2016); da Silva et al. (2017) |
| GAGE1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Seager et al. (2024); Wang et al. (2016); da Silva et al. (2017) |
| GAGE10 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Seager et al. (2024) |
| GAGE12B · HPA | Unsafe | Unsafe | Monaco immune | Jamin et al. (2021) |
| GAGE12C/D/E · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Jamin et al. (2021); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| GAGE12F/G · HPA | Unsafe | Unsafe | HPA immune | Jamin et al. (2021); Loriot et al. (2025) |
| GAGE12H · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025) |
| GAGE12J · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Seager et al. (2024); Wang et al. (2016); da Silva et al. (2017) |
| GAGE13 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Loriot et al. (2025); Seager et al. (2024); da Silva et al. (2017) |
| GAGE2A · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Carter et al. (2023); Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| GAGE2E · HPA | Other:Review | Other:Review | Identity or translation requires review ; Nested or Unsafe-contained sequence | Jamin et al. (2021); Loriot et al. (2025); da Silva et al. (2017) |
| HORMAD1 · HPA | Unsafe | Unsafe | HPA tissue clusters ; DICE immune ; Adult cornea | Bruggeman et al. (2018); Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| HSPB9 · HPA | Unsafe | Unsafe | Normal bulk ; HPA tissue clusters | — |
| IGF2BP3 · HPA | Unsafe | Unsafe | HPA normal protein ; HPA tissue clusters ; Rare vital-tissue cell expression | Bradley et al. (2020); Bruggeman et al. (2018); Chang et al. (2019); Jamin et al. (2021); Wang et al. (2016) |
| LDHC · HPA | Unsafe | Unsafe | Normal bulk ; HPA tissue clusters ; Adult cornea ; Rare vital-tissue cell expression | Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| LIPI · HPA | Unsafe | Unsafe | HPA tissue clusters ; Rare vital-tissue cell expression | — |
| LY6K · HPA | Unsafe | Unsafe | Normal bulk ; HPA tissue clusters ; Adult cornea ; Rare vital-tissue cell expression | Chang et al. (2019); Wang et al. (2016) |
| MAGEA1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Carter et al. (2023); Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Seager et al. (2024); Wang et al. (2016); da Silva et al. (2017) |
| MAGEA10 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Carter et al. (2023); Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Seager et al. (2024); Wang et al. (2016) |
| MAGEA11 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Carter et al. (2023); Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| MAGEA12 · HPA | Unsafe | Unsafe | Rare vital-tissue cell expression | Carter et al. (2023); Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Seager et al. (2024); Wang et al. (2016); da Silva et al. (2017) |
| MAGEA2/B · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Jamin et al. (2021); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| MAGEA3 · HPA | Unsafe | Unsafe | HPA tissue clusters | Bruggeman et al. (2018); Carter et al. (2023); Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Seager et al. (2024); Wang et al. (2016); da Silva et al. (2017) |
| MAGEA4 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Bruggeman et al. (2018); Carter et al. (2023); Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Seager et al. (2024); Wang et al. (2016); da Silva et al. (2017) |
| MAGEA6 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Carter et al. (2023); Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| MAGEA8 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| MAGEA9/B · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Jamin et al. (2021); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| MAGEB1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Bruggeman et al. (2018); Carter et al. (2023); Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| MAGEB10 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Wang et al. (2016) |
| MAGEB16 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| MAGEB17 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | — |
| MAGEB18 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Wang et al. (2016); da Silva et al. (2017) |
| MAGEB2 · HPA | Unsafe | Unsafe | HPA tissue clusters | Bruggeman et al. (2018); Carter et al. (2023); Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| MAGEB3 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Wang et al. (2016); da Silva et al. (2017) |
| MAGEB4 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | da Silva et al. (2017) |
| MAGEB5 · HPA | Reproductive Antigen only | Reproductive Antigen only | Reproductive/developmental evidence qualifies; Patient identity is unresolved for potentially qualifying repeated tumor samples | — |
| MAGEB6 · HPA | Unsafe | Unsafe | HPA normal protein | Carter et al. (2023); Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| MAGEB6B · HPA | Cancer Antigen only | Cancer Antigen only | Cancer evidence qualifies; no qualifying reproductive/developmental association recorded | — |
| MAGEC1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Carter et al. (2023); Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| MAGEC2 · HPA | Other:Review | Other:Review | Normal-expression evidence blocks admission | Carter et al. (2023); Chang et al. (2019); Loriot et al. (2025); Seager et al. (2024); Wang et al. (2016); da Silva et al. (2017) |
| MAGEC3 · HPA | Unsafe | Unsafe | Normal bulk ; HPA tissue clusters ; Rare vital-tissue cell expression | — |
| NY-ESO-1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Jamin et al. (2021); Loriot et al. (2025); Seager et al. (2024); Wang et al. (2016); da Silva et al. (2017) |
| OIP5 · HPA | Unsafe | Unsafe | Normal bulk ; HPA tissue clusters ; Monaco immune ; Rare vital-tissue cell expression | Chang et al. (2019); Wang et al. (2016) |
| PAGE1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| PAGE2 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Carter et al. (2023); Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| PAGE2B · HPA | Unsafe | Unsafe | HPA tissue clusters | Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| PAGE3 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019) |
| PAGE4 · HPA | Unsafe | Unsafe | Normal bulk | — |
| PAGE5 · HPA | Unsafe | Unsafe | HPA tissue clusters | Carter et al. (2023); Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| PBK · HPA | Unsafe | Unsafe | Normal bulk ; HPA tissue clusters ; Adult cornea ; Rare vital-tissue cell expression | Chang et al. (2019); Wang et al. (2016); da Silva et al. (2017) |
| PIWIL1 · HPA | Unsafe | Unsafe | HPA tissue clusters | Chang et al. (2019); Jamin et al. (2021); Wang et al. (2016); da Silva et al. (2017) |
| PIWIL2 · HPA | Unsafe | Unsafe | Normal bulk ; HPA tissue clusters ; Adult cornea ; Rare vital-tissue cell expression | Bruggeman et al. (2018); Chang et al. (2019); Wang et al. (2016) |
| PIWIL4 · HPA | Unsafe | Unsafe | HPA normal protein ; Normal bulk ; HPA tissue clusters ; DICE immune ; Rare vital-tissue cell expression | — |
| PLAC1 · HPA | Unsafe | Unsafe | Rare vital-tissue cell expression | Bradley et al. (2020); Wang et al. (2016) |
| PRAME · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Bruggeman et al. (2018); Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| ROPN1 · HPA | Unsafe | Unsafe | HPA tissue clusters | Bruggeman et al. (2018); Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| ROPN1B · HPA | Unsafe | Unsafe | Normal bulk ; HPA tissue clusters ; Adult cornea | Bruggeman et al. (2018); Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| ROPN1L · HPA | Unsafe | Unsafe | HPA normal protein ; Normal bulk ; HPA tissue clusters ; HPA immune ; Monaco immune ; DICE immune ; Rare vital-tissue cell expression | Chang et al. (2019); Jamin et al. (2021); Wang et al. (2016) |
| SAGE1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Carter et al. (2023); Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| SPA17 · HPA | Unsafe | Unsafe | HPA normal protein ; Normal bulk ; HPA tissue clusters ; Adult cornea ; Rare vital-tissue cell expression | Chang et al. (2019); Wang et al. (2016); da Silva et al. (2017) |
| SPACA1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Carter et al. (2023); Chang et al. (2019); Wang et al. (2016); da Silva et al. (2017) |
| SPAG1 · HPA | Unsafe | Unsafe | HPA normal protein ; Normal bulk ; HPA tissue clusters ; DICE immune ; Adult cornea ; Rare vital-tissue cell expression | Jamin et al. (2021) |
| SPAG9 · HPA | Unsafe | Unsafe | HPA normal protein ; Normal bulk ; HPA tissue clusters ; HPA immune ; Monaco immune ; DICE immune ; Adult cornea ; Rare vital-tissue cell expression | Garg et al. (2007) |
| SPANXA1/2 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Jamin et al. (2021); Wang et al. (2016); da Silva et al. (2017) |
| SPANXB1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Jamin et al. (2021); Loriot et al. (2025) |
| SPANXC · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Carter et al. (2023); Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| SPANXD · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Carter et al. (2023); Chang et al. (2019); Loriot et al. (2025) |
| SPANXN1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019) |
| SPANXN2 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | — |
| SPANXN3 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Wang et al. (2016) |
| SPANXN4 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | — |
| SPANXN5 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Wang et al. (2016) |
| SSX1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| SSX2/B · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Jamin et al. (2021); Loriot et al. (2025); Seager et al. (2024); Wang et al. (2016); da Silva et al. (2017) |
| SSX3 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Carter et al. (2023); Chang et al. (2019); Jamin et al. (2021); Wang et al. (2016); da Silva et al. (2017) |
| SSX4/B · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Jamin et al. (2021); da Silva et al. (2017) |
| SSX5 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| SSX7 · HPA | Unsafe | Unsafe | Normal bulk | Wang et al. (2016) |
| SYCP1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| SYCP2 · HPA | Unsafe | Unsafe | Normal bulk ; HPA tissue clusters ; Monaco immune ; DICE immune ; Rare vital-tissue cell expression | Chang et al. (2019); Jamin et al. (2021); Wang et al. (2016) |
| SYCP3 · HPA | Unsafe | Unsafe | HPA tissue clusters ; DICE immune ; Rare vital-tissue cell expression | Bruggeman et al. (2018); Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| TEX101 · HPA | Unsafe | Unsafe | Normal bulk ; HPA tissue clusters ; HPA immune ; Monaco immune | Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016); da Silva et al. (2017) |
| TPTE · HPA | Unsafe | Unsafe | Rare vital-tissue cell expression | Bruggeman et al. (2018); Jamin et al. (2021); da Silva et al. (2017) |
| TSGA10 · HPA | Unsafe | Unsafe | Normal bulk ; HPA tissue clusters ; DICE immune ; Adult cornea ; Rare vital-tissue cell expression | Chang et al. (2019); Wang et al. (2016) |
| TSPY1 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016) |
| TSPY10/3 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Loriot et al. (2025); Wang et al. (2016) |
| TSPY2 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016) |
| TSPY4 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Loriot et al. (2025); Wang et al. (2016) |
| TSPY8 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | — |
| TSPY9 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Loriot et al. (2025) |
| XAGE1A/B · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Loriot et al. (2025); Seager et al. (2024) |
| XAGE2 · HPA | Unsafe | Unsafe | Normal bulk ; HPA tissue clusters ; Rare vital-tissue cell expression | — |
| XAGE3 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Wang et al. (2016) |
| XAGE5 · HPA | CTA | CTA | Cancer and reproductive/developmental evidence qualify | Chang et al. (2019); Loriot et al. (2025); Wang et al. (2016) |